Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Development of Modified Phenylalanine Ammonia-lyase for the Treatment of Phenylketonuria

  • Kim, Woo-Mi (Department of Pharmacology, Kosin University College of Medicine)
  • Published : 2009.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Phenylketonuria (PKU) is an inherited metabolic disorder caused by mutations in the phenylalanine catabolic enzyme, phenylalanine hydroxylase (PAH). The use of phenylalanine ammonia-lase (PAL) by oral and parenteral routes as a therapeutic drug for PKU has been severely limited due to inactivation by intestinal proteolysis and immune reactions. PEGylation was applied to PAL to reduce the degrees of antigenicity and proteolytic inactivation. Kinetic experiments with native PAL and pegylated PALs were performed, and pH stability, temperature stability, and protease susceptibility were evaluated. Enzyme linked immunosorbent assay (ELISA) was carried out to measure the immune complex between pegylated PALs and antiserum that had been extracted from a PAL-immunized mouse. Pegylated PAL, especially branched pegylated PAL (10 kDa, 1:32), was more active for phenylalanine and more stable in pancreatic proteases than native PAL. Native PAL was optimal at pH 8.5, corresponding to the average pH range of the small intestine; the same finding was noted for pegylated PALs. All linear and branched pegylated PALs had low reactivity with mouse antiserum, especially the 1:16 formulation with linear 5-kDa PEG and the 1:32 formulation with branched 10-kDa PEG. Therefore, we suggest the 1:32 formulation with branched 10-kDa PEG as the most promising formulation for enzyme replacement therapy.

Keywords

References

  1. Ambrus, C. M. et al. (1983). In vivo safety of hollow fiber enzyme-reactors with immobilized phenylalanine ammonialyase in a large animal model for phenylketonuria. J. Pharmacol. Exp. Ther. 224, 598-602
  2. Bos, E. S., van der Doelen, A. A., van Rooy, N. and Schuurs, A. H. (1981). 3,3',5,5' -Tetramethylbenzidine as an Ames test negative chromogen for horse-radish peroxidase in enzymeimmunoassay. J. Immunoassay. 2, 187-204 https://doi.org/10.1080/15321818108056977
  3. Bourget, L. and Chang, T. M. (1984). Artificial cell-microencapsulated phenylalanine ammonia-lyase. Appl. Biochem. Biotechnol. 10, 57-59 https://doi.org/10.1007/BF02783735
  4. Bourget, L. and Chang, T. M. (1986). Phenylalanine ammonialyase immobilized in microcapsules for the depletion of phenylalanine in plasma in phenylketonuric rat model. Biochim. Biophys. Acta. 883, 432-438 https://doi.org/10.1016/0304-4165(86)90281-3
  5. Bourget, L. and Chang, T. M. (1989). Effects of oral administration of artificial cells immobilized phenylalanine ammonialyase on intestinal amino acids of phenylketonuric rats. Biomater. Artif. Cells Artif. Organs. 17, 161-181 https://doi.org/10.3109/10731198909118278
  6. Chang, T. M., Bourget, L. and Lister, C. (1995). A new theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria. Artif. Cells Blood Substit. Immobil. Biotechnol. 23, 1-21 https://doi.org/10.3109/10731199509117665
  7. Delgado, C., Francis, G. E. and Fisher, D. (1992). The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 9, 249-304
  8. Fritz, R. R., Hodgins, D. S. and Abell, C. W. (1976). Phenylalanine ammonia-lyase. Induction and purification from yeast and clearance in mammals. J. Biol. Chem. 251, 4646-4650
  9. Gilbert, H. J. and Jack, G. W. (1981). The effect of proteinases on phenylalanine ammonia-lyase from the yeast Rhodotorula glutinis. Biochem. J. 199, 715-723 https://doi.org/10.1042/bj1990715
  10. Gilbert, H. J. and Tully, M. (1985). Protection of phenylalanine ammonia-lyase from proteolytic attack. Biochem. Biophys. Res. Commun. 131, 557-563 https://doi.org/10.1016/0006-291X(85)91272-0
  11. Greenwald, R. B., Choe, Y. H,, McGuire, J. and Conover, C. D. (2003). Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55, 217-250 https://doi.org/10.1016/S0169-409X(02)00180-1
  12. Harris, J. M. and Chess, R. B. (2003). Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discovery. 2, 214-221 https://doi.org/10.1038/nrd1033
  13. Hershfield, M. S., Chaffee, S., Koro-Johnson, L., Mary, A., Smith, A. A. and Short, S. A. (1991). Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl. Acad. Sci. USA. 88, 7185-7189 https://doi.org/10.1073/pnas.88.16.7185
  14. Hoskins, D. S. (1968) The presence of a carbonyl group at the active site of L-phenylalanine ammonia-lyase. Biochem. Biophys. Res. Commun. 32, 246-253 https://doi.org/10.1016/0006-291X(68)90376-8
  15. Hoskins, J. A. and Gray, J. (1982). Phenylalanine ammonialyase in the management of phenylketonuria: the relationship between ingested cinnamate and urinary hippurate in humans. Res. Commun. Chem. Pathol. Pharmacol. 35, 275-282
  16. Hoskins, J. A., Jack, G., Wade, H. E., Peiris, R. J., Wright, E. C., Starr, D. J. and Stern, J. (1980). Enzymatic control of phenylalanine intake in phenylketonuria. Lancet. 23, 392-394
  17. Mehvar, R. (2000). Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J. Pharm. Sci. 3, 125-136 https://doi.org/10.1002/jps.3080030132
  18. Monfardini, C., Schiavon, O., Caliceti, P., Morpurgo, M., Harris, J. M. and Veronese, F. M. (1995). A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug. Chem. 6, 62-69 https://doi.org/10.1021/bc00031a006
  19. Sarkissian, C. N., Shao, Z., Blain, F., Peevers, R., Su, H., Heft, R., Chang, T. M. and Scriver, C. R. (1999). A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc. Natl. Acad. Sci. USA. 96, 2339-2344 https://doi.org/10.1073/pnas.96.5.2339
  20. Scriver, C. R. and Kaufman, S. (2001). The metabolic and molecular bases of inherited disease. pp. 1667-1724. McGraw-Hill Press, New York
  21. Veronese, F. M. (2001). Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 22, 405-417 https://doi.org/10.1016/S0142-9612(00)00193-9
  22. Veronese, F. M., Caliceti, P., Schiavon, O. and Sergi, M. (2002). Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv. Drug Deliv. Rev. 54, 587-606 https://doi.org/10.1016/S0169-409X(02)00029-7
  23. Veronese, F. M., Monfardini, C., Caliceti, P., Schiavon, O., Scrawen, M. D. and Beer D. (1996). Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxypoly (ethylene glycol). J. Control Release. 40, 199-209 https://doi.org/10.1016/0168-3659(95)00185-9